Preoperative Burosumab With Delayed FGF23 Recovery and High Postoperative Bone Turnover in Tumor-Induced Osteomalacia
JCEM Case Reports · 08.01.2026 · 4 (2)
DOI: 10.1210/jcemcr/luaf296 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 27.01.2026. Verfasst von Heng Yeh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Bassett Medical Center, Cooperstown, NY 13326, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by the overproduction of fibroblast growth factor 23 (FGF23) from phosphaturic mesenchymal tumors (PMTs). Clinical features include skeletal deformities, bone mineral density (BMD) loss, and debilitating myopathy. Hypophosphatemia and low 1,25(OH)2D levels are hallmark biochemical findings. We report a 46-year-old man with delayed tumor localization who received preoperative burosumab. Postoperatively, he developed transient mild hypocalcemia, persistently elevated alkaline phosphatase and parathyroid hormone, and prolonged FGF23 elevation for 6 months despite normalized serum phosphate and improved BMD. Burosumab can interfere with FGF23 assays and may cause extremely high in vivo FGF23 values for months. Alternative biochemical markers should be pursued postoperatively in patients who received burosumab before surgery. A high bone turnover state resembling hungry bone syndrome may occur after PMT resection. Awareness of these postoperative biochemical changes and the effects of burosumab on FGF23 assays is essential for monitoring TIO recovery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Bassett Medical Center, Cooperstown, NY 13326, USA.
- Memorial Healthcare System, Internal Medicine Residency Program, Pembroke Pines, FL 33028, USA.
- Department of Adult and Pediatric Endocrinology, Memorial Healthcare System, Hollywood, FL 33021, USA.
ORCID-Profile: Heng Yeh, Htoo Myat Nge, Asmita Ghimire, Chelsea Gordner
Zitieren
APA
Yeh, H., Nge, H. M., Ghimire, A., & Gordner, C. (2026). Preoperative Burosumab With Delayed FGF23 Recovery and High Postoperative Bone Turnover in Tumor-Induced Osteomalacia. JCEM Case Reports, 4(2). https://doi.org/10.1210/jcemcr/luaf296
Vancouver
Yeh H, Nge HM, Ghimire A, Gordner C. Preoperative Burosumab With Delayed FGF23 Recovery and High Postoperative Bone Turnover in Tumor-Induced Osteomalacia. JCEM Case Reports. 2026;4(2). doi:10.1210/jcemcr/luaf296
BibTeX
@article{Yeh2026,
author = {Yeh, Heng and Nge, Htoo Myat and Ghimire, Asmita and Gordner, Chelsea},
title = {Preoperative Burosumab With Delayed FGF23 Recovery and High Postoperative Bone Turnover in Tumor-Induced Osteomalacia},
journal = {JCEM Case Reports},
year = {2026},
volume = {4},
number = {2},
doi = {10.1210/jcemcr/luaf296}
}
EUVIMED